PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (P

(51) International Patent Classification 5 :		(11) International Publication Number: WO 93
A61K 47/36	A1	(43) International Publication Date: 2 September 1993 (

(21) International Application Number: PCT/CA93/00061

(22) International Filing Date: 16 February 1993 (16.02.93)

(30) Priority data:
2,061,703 20 February 1992 (20.02.92) CA

(71) Applicant *(for all designated States except US):* NOR-PHARMCO INC. [CA/CA]; 890 Yonge Street, Second Floor, Toronto, Ontario M4W 3P4 (CA).

(72) Inventors; and
(75) Inventors/Applicants *(for US only) :* FALK, Rudolf, Edgar [CA/CA]; 40 Riverview Drive, Toronto, Ontario M4N 3C7 (CA). ASCULAI, Samuel, Simon [US/CA]; 53 McCaul Street, Apartment #TH13, Toronto, Ontario M6M 2B6 (CA). KLEIN, Ehud, Shmuel [IL/IL]; 79 Hagalil Street, Ganei Tikva, Givat Savyon 55900 (IL). HARPER, David, William [GB/CA]; 76 Alexander Drive, Oakville, Ontario L6J 4B4 (CA). HOCHMAN, David [CA/CA]; 180 Rosedale Heights Drive, Thornhill, Ontario L4J 4W4 (CA). PURSCHKE, Don [CA/CA]; 66 Pacific Avenue, Apartment # 215, Toronto, Ontario M6P 2P4 (CA).

(74) Agents: HUGHES, Ivor, M. et al.; 175 Commer Drive, Suite 200, Thornhill, Ontario L3T 7P6 (

(81) Designated States: AT, AU, BB, BG, BR, CA, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, UA, US, European patent (AT, BE, CH, DE, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), O tent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, TD, TG).

Published
With international search report.

(54) Title: FORMULATIONS CONTAINING HYALURONIC ACID

(57) Abstract

Pharmaceutical compositions from which effective non-toxic (to the patient) dosage amounts may be taken and ap the skin and/or exposed tissue of a human, each effective dosage amount comprising pharmaceutical excipients suitable f cal application, an effective non-toxic dosage amount of a drug to treat and to assist to resolve a disease and/or conditio skin and/or exposed tissue of a human and an effective non-toxic dosage amount of hyaluronic acid and/or salts thereof homologues, analogues, derivatives, complexes, esters, fragments, and/or sub-units of hyaluronic acid sufficient to trans facilitate or cause the transport of) the drug, to a site in the skin including epidermis or exposed tissue of a disease or co for percutaneous transport into the skin and/or exposed tissue to accumulate and remain there for a prolonged period and which is systemic independent acting.

This Sheet Has Been Replaced

